Results 101 to 110 of about 1,458 (171)

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I. [PDF]

JCO Precis Oncol
Kummar S, Song Z, Reiss KA, Ford JM, Chen L, Rolig AS, Zwiebel JA, Gore SD, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Gross J, Brunnquell D, Jackson LF, Williams PM, Hamilton SR, Takebe N, Brufsky A, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.   +26 more
europepmc   +1 more source

Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation. [PDF]

Signal Transduct Target Ther
Camps-Fajol C, Minguillón J, Surrallés J.   +2 more
europepmc   +1 more source

WEE1 kinase in cancer: Molecular mechanisms and inhibitor insights. [PDF]

EXCLI J
Kumar A, Paudel KR, Kaur R, Bhatia R.
europepmc   +1 more source

Integrative Transcriptomics Identifies Ubiquitination-Related Genes BIRC2, COPS5, and TBK1 as Novel Biomarkers of T-Cell Dysregulation in Amyotrophic Lateral Sclerosis

Journal of Inflammation Research
Ailing Jiang, Yanzhen Huang, Xianting Que, Chonglin Li, Ziqun Lin, Wen Huang Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaCorrespondence: Wen Huang, Department of ...
Jiang A, Huang Y, Que X, Li C, Lin Z, Huang W   +5 more
doaj  

G2/M Checkpoint Dependency in High-Grade Serous Tubo-Ovarian Carcinoma: Mechanisms and Therapeutic Implications. [PDF]

Genes (Basel)
Tian Z, McLean K.
europepmc   +1 more source

WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. [PDF]

EMBO Mol Med
Buzo K, Bizzozero L, Lentini M, Opattova A, Hernández-Suárez B, Torres M, Chiabotto G, Nisticò C, De Lazzari G, R Zanella E, Grasso G, Mariella E, Durinikova E, Linnebacher M, Sartore-Bianchi A, Siena S, Trusolino L, Bardelli A, Arena S.   +18 more
europepmc   +1 more source

NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors. [PDF]

Mol Cancer Ther
Nguyen TT, Nandwana NK, Srikanth YVV, Bagnyukova T, Chkhalo O, Cai KQ, Lamperelli J, Pirestani S, Mehra MK, Burtness BA, Borghaei H, Akunuri R, Cassel J, Lu L, Salvino JM, Golemis EA.   +15 more
europepmc   +1 more source

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer. [PDF]

Front Oncol
Karam MN, Hajj J, Crane CH, Ramia P, Geara F, Hamadeh N, Scott JG, Grobmyer S, Almond R, O'Reilly EM, Hajj C.   +10 more
europepmc   +1 more source

BAYESIAN EMPIRICAL LIKELIHOOD FOR ULTRA-HIGH DIMENSIONAL VARIABLE SELECTION WITH APPLICATION TO DRUG SENSITIVITY. [PDF]

Ann Appl Stat
Xu C, Lu Z, Cheng Y, Song Q, Zhao Y, Wang X.   +5 more
europepmc   +1 more source

Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer. [PDF]

Target Oncol
Johnson ML, Dakhil SR, Beck JT, Sadiq A, Menon S, Mugundu GM, Chmielecki J, Spigel DR.   +7 more
europepmc   +1 more source